Media Contact

Larissa Doucette

The Pharmacy Compounding Advisory Committee will meet on February 23-24, 2015 to provide advice on scientific, technical, and medical issues concerning drug compounding under the Drug Quality and Security Act (DQSA), Food and Drug Administration (FDA) announced in the Federal Register. The committee will discuss the list of bulk drug substances that may not be compounded under exemptions provided by the Federal Food, Drug, and Cosmetic Act because the drug product or their components have been withdrawn or removed from the market because they were found to be unsafe or not effective, as well as six substances nominated for inclusion on the list of drug substances that may be used for compounding under the exemptions. Interested individuals may present or submit written information on issues before the committee by following the instructions provided on the FDA website.